AVITA Medical Inc. is a commercial stage regenerative tissue company in the United States, Australia, and the United Kingdom. The company is headquartered in Valencia, California.
| Revenue (TTM) | $75.63M |
| Gross Profit (TTM) | $61.68M |
| EBITDA | $-32.76M |
| Operating Margin | -31.60% |
| Return on Equity | -1746.00% |
| Return on Assets | -41.60% |
| Revenue/Share (TTM) | $2.52 |
| Book Value | $-0.90 |
| Price-to-Book | 11.77 |
| Price-to-Sales (TTM) | 6.87 |
| EV/Revenue | 6.99 |
| EV/EBITDA | -6.17 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 17.80% |
| Shares Outstanding | $31.31M |
| Float | $30.46M |
| % Insiders | 1.52% |
| % Institutions | 16.49% |
Volatility is currently expanding
Avita Medical NASDAQ: RCEL raised its full-year revenue forecast for the second consecutive quarter after third-quarter sales rose 53% from a year earlier, driven by demand for its RECELL wound treatment system and growing adoption of Cohealyx.
CMS finalizes nationally published physician valuations; CMS's four-code structure simplifies procedure reporting beginning January 1, 2027 VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized national physician valuations for skin cell suspension autograft (SCSA) procedures performed using RECELL® under the Calendar Year 2027 Medicare Physician Fee Schedule.
VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Thursday, November 5, 2026.
Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have averaged more than half of the S&P 500's annual returns with more positive years than all the other quarters. Small cap healthcare/biotech, technology, and consumer cyclicals—like PRME, CRNC, and FOSL—are highlighted as early breakout candidates with strong institutional interest and analyst targets.
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that its senior management will participate in the following investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference – Thursday, September 10, 2026 | Investor meetings with Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer | New York Morgan Stanley 24th Annual Global Healthcare Conference – Wednesday, September 16, 2026 | 1:05 p.m.
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
AVITA Medical's reimbursement is now becoming more predictable. I believe this removes one of their main adoption barriers going forward. The RECELL GO international rollout and PermeaDerm's positive clinical economics also broaden RCEL's long-term potential. Management said they should reach their cash flow breakeven target by Q4 2026, which would further derisk the stock as a whole.
Avita Medical NASDAQ: RCEL presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RCEL and any ticker you trade — then tracks every position and per-strategy win rate.
